coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
umifenovir
antivir
drug
use
treat
influenza
russia
china
studi
aim
investig
effect
safeti
umifenovir
retrospect
studi
perform
nonicu
ward
jinyintan
hospit
februari
march
confirm
realtim
reversetranscriptas
polymerasechainreact
rtpcr
assay
pharyng
swab
specimen
confirm
patient
divid
umifenovir
group
control
group
accord
use
umifenovir
main
outcom
neg
rate
pharyng
swab
test
within
week
admiss
well
durat
viru
turn
neg
neg
time
defin
first
day
neg
test
nucleid
acid
neg
consecut
test
total
patient
includ
umifenovir
group
control
group
baselin
clinic
laboratori
characterist
compar
two
group
patient
umifenovir
group
test
neg
within
day
admiss
number
control
group
median
time
onset
symtom
turn
neg
day
interquartil
rang
iqr
umifenovir
group
day
iqr
control
group
p
patient
umifenovir
group
longer
hospit
stay
patient
control
group
day
iqr
vs
day
iqr
death
sever
advers
reaction
found
group
umifenovir
might
improv
prognosi
acceler
clearanc
nonicu
patient
random
control
clinic
trial
need
assess
efficaci
umifenovir
coronaviru
diseas
new
form
respiratori
disord
caus
sever
acut
respiratori
syndrom
coronaviru
specif
vaccin
treatment
symptomat
support
treatment
main
medic
approach
patient
envelop
positivesens
rna
viru
belong
human
coronavirus
hcov
two
member
hcov
name
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
alreadi
caus
sever
epidem
worldwid
previou
studi
shown
sarscov
genom
sequenc
highli
homolog
umifenovir
c
previou
clinic
basic
research
show
umifenovir
could
reduc
reproduct
sar
viru
vitro
howev
use
umifenovir
remain
unclear
import
evalu
effect
safeti
umifenovir
due
lack
antivir
treatment
novel
diseas
present
retrospect
studi
aim
compar
clinic
characterist
outcom
patient
without
umifenovir
treatment
exclus
criteria
patient
use
medic
potenti
antivir
activ
follow
data
collect
electron
medic
record
age
sex
chronic
medic
ill
symptom
laboratori
find
chest
comput
tomograph
ct
scan
main
treatment
time
symptom
onset
time
first
neg
result
pharyng
swab
length
hospit
stay
onset
diseas
defin
first
day
symptom
occur
neg
time
defin
first
day
neg
test
nucleid
acid
neg
consecut
pharyng
swab
test
rtpcr
data
collect
review
train
team
design
physician
baselin
data
refer
clinic
data
time
admiss
laboratori
data
within
first
hour
admiss
biochem
index
test
report
second
day
hospit
imag
ct
scan
within
day
admiss
day
treatment
collect
ct
scan
review
score
two
physician
major
respiratori
medicin
score
ct
scan
assess
base
previou
report
tabl
supplementari
inform
score
lobe
total
possibl
score
main
outcom
neg
rate
pharyng
swab
test
within
week
admiss
well
durat
viru
turn
neg
second
outcom
chang
ct
score
treatment
patient
receiv
symptomat
treatment
includ
appropri
support
care
regular
clinic
laboratori
monitor
standard
protocol
monitor
patient
hospit
follow
pharyng
swab
nucleic
acid
test
done
everi
day
patient
normal
bodi
temperatur
improv
symptom
admiss
chest
ct
examin
perform
within
day
admiss
day
hospit
accord
without
umifenovir
treatment
patient
divid
umifenovir
group
control
group
patient
umifenovir
group
receiv
umifenovir
gram
three
time
day
level
alt
alanin
transaminas
ast
aspart
aminotransferas
creatinin
treatment
collect
day
hospit
order
clarifi
impact
umifenovir
patient
differ
sever
divid
patient
moder
subgroup
sever
subgroup
accord
criteria
diagnosi
treatment
program
trial
seventh
edit
patient
defin
sever
met
follow
criteria
respiratori
distress
breath
frequenc
breath
min
rest
state
mean
oxygen
satur
arteri
blood
oxygen
partial
pressur
oxygen
concentr
mmhg
mmhg
kpa
other
includ
moder
group
patient
need
mechan
ventil
vasopressor
defin
critic
ill
patient
statist
analys
perform
use
spss
categor
variabl
describ
percentag
continu
variabl
describ
use
median
interquartil
rang
valu
mean
continu
variabl
compar
use
independ
group
test
data
normal
distribut
otherwis
mannwhitney
test
use
categor
variabl
compar
use
test
fisher
exact
test
use
data
limit
signific
recogn
p
valu
less
total
patient
hospit
ward
februari
march
reason
subject
exclud
final
analysi
follow
treatment
lopinavir
ritonavir
treatment
redciv
tabl
major
given
umifenovir
upon
admiss
other
given
within
first
hour
admiss
nucleid
acid
test
upon
admiss
report
second
day
hospit
day
tabl
patient
sever
diseas
given
umifenovir
fare
better
sever
patient
control
group
tabl
tabl
retrospect
studi
found
umifenovir
treatment
shorten
neg
time
length
hospit
stay
nonicu
hospit
patient
sever
side
effect
found
umifenovir
treatment
vaccin
avail
urgent
find
effect
medicin
umifenovir
broadspectrum
antivir
agent
propos
potenti
medic
vitro
studi
show
umifenovir
significantli
inhibit
china
prevent
treatment
guidelin
wide
use
clinic
treatment
effect
question
studi
median
time
onset
diseas
first
neg
result
pharyng
swab
sarscov
differ
two
group
suggest
umifenovir
acceler
viral
clearanc
baselin
ct
score
higher
umifenovir
group
stratifi
analysi
base
ct
score
perform
correct
bia
two
group
result
stratifi
analysi
support
umifenovir
therapi
superior
support
therapi
treatment
term
radiolog
improv
result
consist
previou
studi
found
day
umifenovir
treatment
increas
neg
rate
pharyng
swab
test
within
week
studi
even
patient
longer
treatment
durat
sever
limit
studi
first
singl
center
retrospect
studi
small
sampl
size
observ
studi
bia
conclus
could
subject
second
pharyng
swab
collect
everi
day
due
limit
medic
resourc
pathogen
nucleic
acid
quantifi
well
third
studi
includ
patient
moder
sever
effect
umifenovir
mild
critic
patient
confirm
studi
conclus
compar
symptomat
support
treatment
addit
umifenovir
found
shorten
durat
neg
time
improv
prognosi
nonicu
patient
conclus
need
verifi
random
control
clinic
trial
author
disclos
conflict
interest
qichang
lin
design
studi
revis
manuscript
ningfang
lian
xie
hansheng
analysi
data
prepar
manuscript
jianm
zhao
collect
data
perform
manuscript
draft
jiefeng
huang
search
literatur
analysi
data
su
lin
review
result
made
critic
comment
manuscript
